STOCK TITAN

CymaBay Therapeutics, Inc. - CBAY STOCK NEWS

Welcome to our dedicated page for CymaBay Therapeutics news (Ticker: CBAY), a resource for investors and traders seeking the latest updates and insights on CymaBay Therapeutics stock.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company based in the San Francisco Bay Area, dedicated to developing therapies that address high unmet medical needs in metabolic diseases as well as rare and orphan diseases. The company has been pivotal in creating breakthrough medicines aimed at improving the lives of patients and their families. Seeded with assets from a previous metabolic disease company, CymaBay boasts a robust pipeline thanks to an investment of over $120 million.

CymaBay’s flagship investigational treatment, seladelpar, is designed to manage primary biliary cholangitis (PBC), a chronic liver disease that predominantly affects women. Seladelpar, which has been granted Breakthrough Therapy Designation by the FDA, has demonstrated significant improvements in Phase 3 trials for markers of cholestasis and PBC-related pruritus. Recent developments saw CymaBay submitting a New Drug Application (NDA) for seladelpar to the FDA, requesting Priority Review. If accepted, the FDA aims to complete the review within six months.

In addition to its U.S. application, CymaBay plans to file marketing authorization applications with the European Medicines Agency (EMA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) in the first half of 2024. Seladelpar has already received Priority Medicines (PRIME) status from the EMA.

The company's recent achievements were highlighted by the publication of Phase 3 trial results in The New England Journal of Medicine, showcasing seladelpar’s rapid and sustained improvements in reducing liver injury and pruritus. Financially, CymaBay ended 2023 with $416.2 million in cash, cash equivalents, and investments. Additionally, the pending acquisition of CymaBay by Gilead underscores the potential impact of seladelpar and other pipeline therapies.

The scientific and clinical expertise at CymaBay, coupled with their strategic focus on liver inflammation and fibrosis, positions them at the forefront of therapeutic innovation. Their evidence-based approach and commitment to high-quality standards reflect their dedication to improving patient outcomes and quality of life.

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced participation in three virtual investor conferences, enhancing its investor relations outreach. The conferences include the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 3, 2020. The company is focused on developing therapies for liver diseases, particularly seladelpar, which has received multiple designations from the FDA and EMA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) has announced the start of a global phase 3 study, RESPONSE, evaluating seladelpar for primary biliary cholangitis (PBC). The study aims to enroll 180 patients and assess the efficacy of seladelpar over 52 weeks. Results from the ENHANCE phase 3 study will be presented at The Liver Meeting® 2020. Financial results for Q3 2020 indicate a net loss of $11.4 million, significantly lower than last year, primarily due to reduced R&D expenses. CymaBay holds $161.3 million in cash, sufficient to fund operations into 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
-
Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced a collaboration with the AdventHealth Translational Research Institute to evaluate MBX-2982, a GPR119 agonist, aimed at preventing hypoglycemia in type 1 diabetes (T1D). Funded by a $1.2 million grant from the Helmsley Charitable Trust, the Phase 2a study will assess the drug’s ability to enhance glucagon secretion during insulin-induced hypoglycemia. Previous studies indicate that GPR119 agonists may stimulate glucagon secretion effectively, addressing a significant unmet need in T1D management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
Rhea-AI Summary

CymaBay Therapeutics (CBAY) announced a late-breaking presentation of the ENHANCE Phase 3 study results for seladelpar, focused on primary biliary cholangitis (PBC), to be held at The Liver Meeting Digital Experience™ 2020 from November 13-16. The oral presentation, led by Professor Gideon Hirschfield, aims to share efficacy and safety data regarding seladelpar, an innovative therapy receiving orphan designation from the FDA and EMA for PBC. CymaBay is also preparing to initiate a new global Phase 3 study to support seladelpar's registration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
-
Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) will host a conference call on November 5, 2020, at 4:30 PM ET to discuss Q3 financial results and provide a business update. The company is focused on developing therapies for liver diseases and has a key product, seladelpar, which is under investigation for primary biliary cholangitis (PBC). Seladelpar has received orphan drug designation from the FDA and EMA, along with Breakthrough Therapy Designation from the FDA. For more information, visit their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
conferences earnings
-
Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced participation in three upcoming virtual investor conferences. The Citi’s 15th Annual BioPharma Conference will be held on September 9, 2020. The H.C. Wainwright 22nd Annual Global Investment Conference is scheduled for September 14-16, 2020, while the Cantor Global Healthcare Conference will take place from September 15-17, 2020. CymaBay focuses on developing therapies for liver diseases, including its lead candidate, seladelpar, for primary biliary cholangitis, which has received FDA and EMA designations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
conferences
Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced promising final results from a Phase 2 study of seladelpar for primary biliary cholangitis (PBC), presented at the Digital International Liver Congress™ 2020. The study showed sustained anti-cholestatic effects, with 55% and 69% of patients in the 5/10 mg and 10 mg groups meeting the composite responder criteria after one year. Significant improvement in pruritus was noted, with 93% of patients in the 10 mg group reporting substantial relief. Seladelpar was well tolerated with no serious drug-related adverse events. The findings reaffirm seladelpar's potential as a breakthrough therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
-
Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announces significant developments, including the FDA lifting all clinical holds on seladelpar for nonalcoholic steatohepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis. Positive topline results from the ENHANCE study in PBC demonstrate high efficacy, with 78.2% of patients achieving primary outcomes. The company reported a net loss of $10.7 million for Q2 2020, a decrease from $24 million in Q2 2019. With $168.9 million in cash, CymaBay's finances are stable to fund operations into 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.1%
Tags
-
Rhea-AI Summary

CymaBay Therapeutics has announced that the FDA has lifted clinical holds on its seladelpar Investigational New Drug Applications in NASH, PBC, and PSC. This allows the company to resume clinical development, focusing initially on Phase 3 trials for PBC. The development was halted in November 2019 due to atypical histological findings in a Phase 2 NASH study, but an independent review found no significant safety concerns. The move is viewed as a pivotal step forward for seladelpar, which has shown potential benefits in treating chronic liver diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.07%
Tags
none
Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced new data from a Phase 2 study of seladelpar for treating primary biliary cholangitis (PBC). The study showed significant improvement in pruritus, with 58% and 93% of patients experiencing at least a 20-point decrease in itching after one year with the 5/10 mg and 10 mg doses, respectively. Additionally, 81% and 78% of patients reported improved sleep disturbances associated with itch. Seladelpar, a selective PPARδ agonist, is on clinical hold pending FDA review. The findings were presented at Digestive Disease Week 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.65%
Tags
none

FAQ

What is the market cap of CymaBay Therapeutics (CBAY)?

The market cap of CymaBay Therapeutics (CBAY) is approximately 3.7B.

What is CymaBay Therapeutics, Inc.?

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases and rare and orphan diseases.

Where is CymaBay Therapeutics located?

CymaBay Therapeutics is located in the San Francisco Bay Area.

What is seladelpar?

Seladelpar is CymaBay’s investigational treatment for primary biliary cholangitis (PBC), an inflammatory liver disease.

What recent milestone did seladelpar achieve?

CymaBay recently submitted an NDA for seladelpar to the FDA, which was granted priority review.

What designations has seladelpar received?

Seladelpar has received Breakthrough Therapy Designation from the FDA and Priority Medicines (PRIME) status from the EMA.

What financial position did CymaBay report at the end of 2023?

CymaBay reported having $416.2 million in cash, cash equivalents, and investments as of December 31, 2023.

What is the focus of CymaBay’s research and development?

CymaBay focuses on therapies for liver inflammation, fibrosis, and chronic diseases with high unmet medical needs.

What are the main symptoms of primary biliary cholangitis (PBC)?

The main symptoms of PBC are pruritus (itching) and fatigue, which can be debilitating for some patients.

What is the significance of the Phase 3 trial results for seladelpar?

Phase 3 trial results showed that seladelpar significantly improved markers of cholestasis and pruritus in PBC patients.

Who should be contacted for more information about CymaBay Therapeutics?

For more information, you can contact Theresa Dolge at Evoke Kyne or PJ Kelleher at LifeSci Advisors.

CymaBay Therapeutics, Inc.

Nasdaq:CBAY

CBAY Rankings

CBAY Stock Data

3.73B
110.08M
0.52%
103.13%
5.1%
Biotechnology
Healthcare
Link
United States
Fremont